Characteristics of the mesenchymal subtype of GBM include increased concentrations of NF-κB signaling pathway constituents such as TNF receptor superfamily member 1A [(TNFRSF1A), v-rel reticuloendotheliosis viral oncogene homolog B (RELB), and TNFR1-associated death domain protein (TRADD)], elevated resistance towards chemotherapy and a lesser prognosis as compared to individuals with other GBM types (Verhaak et al., 2010). This evidence concerns the gene NFKB1 and glioblastoma.